Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Home - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 721612 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Printer Friendly
PDF Brochure
Send to Friend
Enquire before Buying
| More
Electronic (PDF)Add to Basket
Hard CopyAdd to Basket
Electronic (Online Access)Add to Basket



The Pharmaceutical Market: Netherlands
Espicom Business Intelligence Ltd, Aug 2008, Pages: 62


  Description  
  Table of Contents  
  Summary  
  Companies Mentioned  
    
   
 Enquire before Buying  
 Send to a Friend  

With cost containment remaining a priority, government policy in the Netherlands has been characterised by various initiatives to liberalise pricing and modify the reimbursement scheme of pharmaceuticals covered under the compulsory health insurance fund. Another principal feature of the market in recent years has been the government's attempts to cut costs through the reduction of drug prices and measures relating to pricing and reimbursement. These measures have led to cost containment and narrowing of the price gap between proprietary and generic medicines.

The Netherlands has had a long reputation on providing a sound base for clinical research. This has been accomplished by a close working relationship between companies and universities. Research is undertaken for third parties in university centres, government and private institutions.

In 2008, the overall Dutch pharmaceutical market is estimated to be worth US$6.3 billion at retail prices, or US$381 per capita. In recent years the market has had many external constraints placed upon it; most notably was the imposition of a 40% price reduction for branded drugs with generic competition.



Customers who bought this item also bought

Netherlands Pharmaceuticals and Healthcare Report Q1 2009

Generics in the Netherlands

Netherlands Pharmaceuticals and Healthcare Report Q4 2008

Netherlands Pharmaceuticals and Healthcare Report Q2 2008

Netherlands Pharmaceuticals and Healthcare Report Q3 2008

Netherlands Pharmaceuticals & Healthcare Report Q1 2008

Pharmaceutical Industry in the Netherlands

India: Pharmaceutical

Chinese Pharmaceutical Industry

Canada Pharmaceutical Industry

The Pharmaceutical Market: Greece

The Pharmaceutical Market: Canada



Top of page


   All rights reserved. � Copyright 2009 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster


Research and Markets RSS Feeds